Abstract
The neoSCORE trial is the first randomized study to compare two versus three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer (NSCLC). While three cycles showed a numerically higher major pathological response (MPR) rate (41.4% vs. 26.9%), the difference was not statistically significant, suggesting a potential benefit for longer treatment that requires larger trials to confirm.
Introduction
For patients with resectable non-small-cell lung cancer (NSCLC), surgery alone often fails to prevent recurrence. Recent breakthroughs have shown that "neoadjuvant" therapy—giving chemo-immunotherapy before surgery—can significantly shrink tumors and improve outcomes. However, a critical clinical question remains: how many cycles are enough? Most trials use between two and four cycles, but there is no consensus on the "sweet spot" that maximizes tumor shrinkage (pathological response) without causing excessive toxicity or delaying life-saving surgery. The neoSCORE trial specifically tests whether adding a third cycle of the PD-1 inhibitor sintilimab plus chemotherapy provides a meaningful boost in efficacy.
Methods
The researchers conducted a prospective, randomized trial (NCT04459611) involving 60 patients with resectable stage IB–IIIA NSCLC. Patients were randomized 1:1 to receive either two cycles (n=29) or three cycles (n=31) of sintilimab plus platinum-based chemotherapy. The study focused on Major Pathological Response (MPR), defined as ≤10% viable tumor cells in the resected specimen, and Pathological Complete Response (pCR), defined as 0% viable tumor cells. Beyond clinical outcomes, the team performed next-generation sequencing (NGS) to identify driver mutations and assessed PD-L1 expression (TPS) to find biomarkers for treatment success.
Results
The study found a clear numerical trend favoring three cycles, with an MPR rate of 41.4% compared to 26.9% in the 2-cycle group. Although this 14.5% increase was not statistically significant (p=0.260), likely due to the small sample size, it suggests a biological advantage for the longer regimen. Pathological Complete Response (pCR) rates were 24.1% for 3 cycles and 19.2% for 2 cycles.
Histology emerged as a major predictor of response. Squamous NSCLC responded significantly better to the regimen than non-squamous NSCLC, with an overall MPR of 51.6% vs. 12.5% (p=0.002). This difference was consistent across both treatment arms. The poor response in non-squamous patients was largely attributed to the presence of driver mutations; 56.5% of non-squamous patients had EGFR mutations, which are known to correlate with poor responses to immune checkpoint inhibitors.
Safety was well-maintained across both groups. Adding a third cycle did not significantly increase the rate of surgical complications or severe treatment-related adverse events (TRAEs), suggesting that the longer regimen is safe for most patients. At 20.4 months of follow-up, the 12-month Overall Survival (OS) remained high in both groups (92.3% for 2-cycle vs. 86.2% for 3-cycle).
Discussion and Future Directions
The primary limitation of the neoSCORE trial is its small sample size, which prevented the observed numerical differences from reaching statistical significance. Additionally, the inclusion of patients with EGFR/ALK mutations—who typically respond poorly to immunotherapy—may have diluted the overall efficacy results.
The authors are moving forward with a Phase 3 trial (NCT05429463) comparing three versus four cycles of neoadjuvant chemo-immunotherapy, specifically focusing on patients with squamous NSCLC to maximize the potential benefit observed in this pilot study.
Summary updated